Golden
Mammoth Biosciences

Mammoth Biosciences

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics.

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics. Their CRISPR platform utilizes two CRISPR proteins: Cas12 and Cas13. The technology being used by Mammoth Bioscience theoretically allows for the detection of any biomarker and/or disease that contains either RNA and/or DNA.







Products and services

Point of care strip

Mammoth biosciences uses technology licensed from UC Berkley and has created a credit card strip capable of delivering health diagnostics at the point of care in hospital and home settings. Their diagnostic strip works by dropping the desired fluid sample onto the strip and waiting for panels on the strip to change colour indicating the test is complete. The CRISPR technology is embedded within the strip, and if or when the desired reaction takes place a coloured molecule is released called a reporter molecule. Different reporter molecules can be present and eventually build up into colours that can be seen with the naked eye. The user then takes a photo of the strip after the reaction is complete (approximately taking 30 minutes) using a smart phone application developed my Mammoth Biosciences. Users can see the results of their strip test using the app. 



Coronavirus diagnostic

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, 2019-nCoV. The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak that began in Wuhan, China in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result. 

Funding

Mammoth Biosciences has received a disclosed amount of $23m in venture capital funding from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital. 



Timeline

August 2018

Mammoth Biosciences raises a $23,000,000 series A round from NFX, Mayfield Fund and 8VC.

Funding rounds

Funding round
Funding round amount (USD)
Funding type
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Andy Lane





Ashley Tehran





Ashley Tehranchi

Founder



Celestine

Investor



James Broughton





Janice Chen





Jennifer Doudna





Lucas Harrington





Pedro Galarza





Trevor Martin





Further reading

Title
Author
Link
Type
Date

After gene-editing, Crispr’s new frontier to detect diseases is closer to becoming a reality

Akshat Rathi





At-home CRISPR kit will diagnose you better than WebMD

Kristin Houser





Jennifer Doudna's latest CRISPR company debuts

Sharon Begley





New startup promises ‘world’s first’ CRISPR-powered disease detection

Dyllan Furness





Xconomy: Home Tests in Mind, Doudna Startup Races Rivals in CRISPR Diagnostics

Alex Lash





Documentaries, videos and podcasts

Title
Date
Link

Mammoth Biosciences launches a CRISPR-powered search engine for disease detection

April 26, 2018

The Mammoth CRISPR Platform

April 26, 2018

Companies

Company
CEO
Location
Products/Services
+ Add new row

News

Title
Author
Date
Publisher
Description
Cormac Sheridan
March 23, 2020
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Megan Molteni
February 5, 2020
Wired
The FDA has given emergency authorization to a new test that promises to help public health labs meet a potential surge in cases.
January 30, 2020
WebWire
Mammoth Biosciences, the company behind the world's first CRISPR-based disease detection platform, today announced an oversubscribed round of $45 million in its Series B. The raise is led by Decheng Capital and has participation from Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8, aMoon, and others. The capital will fuel the company's further development of CRISPR diagnostics and next-generation CRISPR products as it extends its platform to include gene-editing and therapeutics...
December 16, 2019
WebWire
Mammoth Biosciences, the company developing the next generation of CRISPR products, today announced the addition of two key members to its executive team. The expansion of the team supports Mammoth's growth in the life sciences market as the company continues to discover and democratize access to CRISPR systems. Peter Nell, Ph.D. joins Mammoth Biosciences as Chief Business Officer and Head of Therapeutics. In this role, he'll leverage his vast business development and corporate strate...

References